Limbs peripheral traumatisms in prehospital emergency medicine
Conditions
Interventions
Trade Name: Ketamine
Product Name: Ketamine
Pharmaceutical Form: Intravenous infusion
INN or Proposed INN: ketamine chlorhydrate
Concentration unit: mg/kg/h milligram(s)/kilogram/hour
Concentration ty
Sponsors
CHRU de Lille
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Men and women aged 18-70 - Patients who must have a prehospital caring due to limbs peripheral traumatisms - Patients with a EVA score higher or equal to 6 - Patients with a social insurance Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients: - with several traumatisms - with consciousness troubles (Glasgow inferior or equal to 14) - with allergy to ketamine or morphine antecedent - with a contraindication to morphine or ketamine (know by caring): psychiatric antecedents, respiratory, renal, chronic hepatic, coronary insufficiency or heart failure, intracranial hypertension, thyrotoxicosis, eyeball wound, intraocular hypertension - chronic opioids use - pregnancy or menses delay - breast feeding women - who must undergo a loco-regional anesthesia - refusing the protocol or not capable of understanding or bearing (due to a heavy illness) its conditions, or of signing an informed consent - already enrolled in another study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The main objective is to assess the morphinic saving induced by the use of ketamine bolus followed by a continuous perfusion for limbs peripheral traumatisms victims in comparison with a single ketamine dose.;Secondary Objective: 1/To assess the appearance of side effects related to the use of morphine 2/To assess the tolerance of ketamine administered by continuous perfusion in this indication ;Primary end point(s): The primary end point is the diminution of 20% of morphine consumption at T60 or at the end of the caring step if its duration is inferior to one hour in the group treated with a continuous perfusion of ketamine | — |
Countries
France
Outcome results
None listed